Ticagrelor differs from clopidogrel in platelet inhibition primarily because ticagrelor:

• A Directly binds the P2Y12 receptor without requiring hepatic bioactivation ✓
• B Is an irreversible P2Y12 antagonist while clopidogrel is reversible
• C Inhibits P2Y1 receptors rather than P2Y12 receptors
• D Also inhibits ADP release from alpha granules by blocking VMAT2

Explanation

Ticagrelor is a direct-acting, reversible P2Y12 antagonist that does not require hepatic bioactivation (it is not a prodrug). Clopidogrel is an irreversible thienopyridine prodrug requiring CYP2C19-mediated activation to its active thiol metabolite; loss-of-function CYP2C19 polymorphisms reduce clopidogrel efficacy. Ticagrelor's direct action and reversibility (shorter duration, offset within ~72 h) allow more predictable antiplatelet effect and easier perioperative management.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.